CMV reactivation remains a major complication following T-cell depleted (TCD) CMV seropositive allogeneic stem cell transplantation (HSCT) with nearly half of these patients developing recurrent episodes of viremia. 1 Although PCR monitoring for viremia can detect early reactivation, there is currently no established biomarker for predicting CMV recurrence. 2 Previous multiple regression analysis has identified low level CMV-specific CD8 + T-cells (CMV-CD8) as an independent predictor of CMV reactivation, 3 but the role of CMV-specific CD4 + T-cells (CMV-CD4) remains unclear due to the relative lack of direct assays.
In this study, we used HLA class I and novel class II tetramers to analyse 1) the kinetics and phenotype of CMV-CD4 reconstitution in relation to CMV-CD8, 4-7 and 2) to assess the clinical utility of monitoring using both tetramers 8 and a novel putative HLA-independent marker CD57 in 20 CMV-at-risk HLA-DRB1*0701 patients. CMV-CD4 and CMV-CD8 were detectable at low levels early after transplant, but HLA-DRB1*0701 tetramers were custom made to incorporate a CMV-glycoprotein Bderived peptide DYSNTHSTRYV (DYS), 9 that induces strong CMV-CD4 responses ( Figure S1 ). Together with HLA class I multimers, CMV-specific T-cells were monitored up to 36 weeks post-transplant ( Figure 1 ). 18 patients received TCD reduced-intensity conditioning with either Alemtuzumab (pat 16) or ATG (pat 2) (Table S1 and supplemental methods) and 2 patients (pat 04 and 13) had myeloablative chemotherapy. CMV reactivated in 19 patients of which 15 developed viremia within the first 6-7 weeks post-transplant. Ten out of 19 (53%) had a single episode of viral reactivation whilst the rest had multiple viremic relapses (Table 1) ( Figure S2 ). Within the latter group, patients 05 and 06 had prolonged episodes of viremia refractory to anti-viral treatment. Patients 11 and 16 had three and patient 12
had four episodes of viral reactivation. Eight out of 9 of this group had late recurrent reactivations beyond 100 days post-transplant (Table 1 ). In the group with multiple CMV reactivations, 4/9 patients (pat 5, 11, 12, 13) were on systemic steroids for GVHD at the time of viremia whilst only 1/10 (pat 14) with a single episode of CMV reactivation had steroids for GVHD.
Following the first CMV reactivation post-transplant, CMV-CD4 and CMV-CD8 proliferated rapidly and demonstrated parallel kinetics with an approximate 2 log expansion (Table 1 ) ( Figure 1A ,B). It was notable that the magnitude of the CMV-CD4 response was much smaller than that of CMV-CD8. In 11 out of 20 patients with detectable CMV-CD4, the median level at baseline before first reactivation was 0.11% of CD4 + T-cells (range 0.02% to 4%). The corresponding absolute numbers ranged from 0.01 to 0.5x10 3 /ml (median: 0.15x10 3 /ml). This population expanded markedly after viral reactivation and reached a median peak of 4.8% of the CD4 + Tcell pool (range 0.23% to 25%) with corresponding absolute median count of 5.20 x10 3 /ml (range 0.46 to 50x10 3 /ml). The magnitude of CMV-CD4 and CMV-CD8 following CMV reactivation within individual patients exhibited a strong correlation (r=0.75, p<0.0001) ( Figure 1C ).
An important finding was that the magnitude of the CMV-specific T-cell response following the first viral clearance was predictive of protection from recurrent reactivation. CMV-CD4 and CMV-CD8 levels before the first reactivation were low, and although there is up to 5-fold difference in the magnitude of the CMV-CD4 and CMV-CD8 between single reactivation and multiple reactivations, the difference was not significant ( Figure 1D , E).
Instead, levels measured after the resolution of 1 st viremia showed that patients with a single viremic episode had a median peak CMV-CD4 level of 6.2x10 3 /ml, whereas those with multiple episodes of viremia had a median CMV-CD4 level of only 0.04x10 3 /ml (p=0.02) ( Figure 1G ). A similar pattern was seen with CMV-CD8, where the post-viremic count was 41.10x10 3 /ml in patients who gained long term control of reactivation, compared to 4.30x10 3 /ml in those who had multiple reactivations (p=0.049) ( Figure 1H ). These data reveal that the peak CMV-specific T-cell count after the initial episode of viremia can determine the ability to control further reactivations. We estimated the minimum thresholds of CMV-CD4 and CMV-CD8 Since cytokines play a major role in immune reconstitution post HSCT, tetramerpositive cells were co-stained with anti-CD25 (IL2R) and anti-CD127 (IL7R). Neither of these receptors was expressed on CMV-CD8 but a mean 46% of CMV-CD4 retained stable expression of IL7R but not IL2R (Fig 2A) , indicating their capacity to proliferate and their long-term survival.
Studies have shown that a considerable percentage of CMV-CD4 from healthy individuals display cytotoxic activity. 10, 11 Indeed, perforin and granzyme-B expression was observed in 32% and 22% of CMV-CD4 respectively, confirming cytotoxic function within a substantial minority of the population (Figure 2 ). Intracellular analysis of perforin expression suggests that CD4 + CD57 + T-cells represent cytotoxic cells. Both within the CD4 + CD57 + and DYS-specific CD4 + T-cell pools, the median perforin expression was around 50%, in contrast to the whole CD4 population where only a median of 25% of cells expressed perforin ( Figure S4 ).
The expression levels of T-bet, a T-box transcription factor with an important role in development of Th1 cells, was similar in CMV-CD4 and CMV-CD8 at a median of 62% of the antigen-specific population ( Figure 2 ). The CMV-CD4 had higher T-bet expression compared to the global CD4 + T-cell population (p<0.03), supporting the predominant Th1 profile of CMV-CD4. 12 T-bet expression by CMV-CD8 after primary infection has been reported to predict control of recurrent pulmonary CMV viremia in lung transplant patients. 13 However, due to the limited number of frozen cells it was not possible to investigate the relation between CMV-CD4 and CMV-CD8 function.
Nevertheless, as CD4 + T-cells are known to support antibody production, 14 we assessed whether CMV-CD4 reconstitution correlated with the magnitude of the anti-CMV humoral response. A longitudinal analysis did indeed reveal that CMV-specific antibody titres correlated strongly with reconstituting CMV-CD4 (r=0.45, p=0.01) ( Figure S3B ). This likely reflects the helper function of CMV-CD4, and forms part of the immune response against CMV. In addition to the neutralising effect of anti-CMV IgG, they may be involved in ADCC of infected cells mediated by NK cells.
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In conclusion, the study using novel HLA class II tetramers led to three major findings in the setting of reconstitution following HSCT. Firstly CMV-CD4 were shown to reconstitute in parallel with CMV-CD8 following CMV reactivation but at a much lower magnitude. The phenotype of the CMV-CD4 population is that of an effector memory subset and contains a considerable proportion of cytotoxic cells. Finally the enumeration of CMV-CD4 and CMV-CD8 responses after first episode of viral reactivation is predictive of the subsequent risk of recurrence.
Currently available CMV-specific tetramers cover around 80% of Caucasian tissue types. The addition of the HLA-DRB1*0701 tetramer expands the coverage but may also improve the prediction of reactivation. Larger prospective trials are needed to confirm the utility of these assays as biomarkers for risk-stratifying patients into a low risk group with high CMV-T-cell levels that do not suffer from further reactivation, and into a high risk group with low CMV-T-cell levels at high risk of recurrent CMV reactivation. The assay could help guide appropriate introduction of prophylactic Tcell immunotherapy or second line anti-viral drug therapy.
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Statistical Analysis
GraphPad Prism software version 5 (GraphPad Software, La Jolla, USA) was used for preparation of graphs and non-parametric statistical analysis. 
